Navigation Links
PI3K/mTOR pathway proteins tied to poor prognosis in breast cancer
Date:4/1/2012

CHICAGO - Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR Annual Meeting 2012.

All of the aberrantly activated translational proteins are regulated by the PI3K/mTOR molecular signaling pathway, which has been implicated in development and progression of several cancers.

More recently, mTOR activation has been tied to resistance to standard endocrine therapy in estrogen-receptor positive breast cancer, said Funda Meric-Bernstam, M.D., professor in MD Anderson's Department of Surgical Oncology, who presented the research at AACR.

"These data underline the importance of the PI3K/mTOR pathway in hormone receptor-positive breast cancer and suggest potential new prognostic factors and therapeutic targets," said Meric-Bernstam, who also is medical director of MD Anderson's Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.

Two drugs that inhibit mTOR, everolimus and temsirolimus, are approved for treatment of certain cancers and there are dozens of other agents in clinical trials, she said.

Cancer cells rely on increased protein synthesis

Genes express messenger RNA, which is in turn processed through a cell's ribosomes to produce a specific protein, a step called translation.

"Cancer cells need a lot of protein synthesis to grow and survive," Meric-Bernstam said. She and colleagues systematically analyzed several major translation-regulating proteins in tumors from 190 patients with stage 1 to stage 3 hormone receptor-positive breast cancer. Median follow-up was 96 months.

They found four aberrations that were predictors of overall survival. They remained significant even after multivariable analysis accounting for other factors such as age and node-positive status that also affect survival. They are:

  • Increased phosphorylation of ribosomal protein S6 (pS6) and of translation initiation factor 4E-binding protein 1 (p4E-BP1).
  • Increased expression of eukaryotic elongation factor 2 kinase (eEF2K).
  • Decreased expression of programmed cell death protein 4 (pdcd4).

Their findings, if validated by additional studies, could lead to markers that help select patients who may have a high risk of relapse if treated with traditional endocrine therapy alone and identify those who might benefit from an additional targeted therapy, Meric-Bernstam noted.

Results from a major phase III clinical trial presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium showed that the mTOR inhibitor everolimus increased progression-free survival when combined with the hormonal therapy exemestane to treat resistant hormone receptor-positive breast cancer.

"As we understand how to select patients better we'll be able to more efficiently use these targeted therapies to improve outcomes for breast cancer patients," Meric-Bernstam said.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Scientists link 2 cancer-promoting pathways in esophageal cancer
2. Pancreatic Cancer Action Network-AACR Pathway to Leadership grants
3. PCP genetic pathway acts as stop sign for cell growth
4. New pathway found for regulation of blood vessel growth in cancer
5. Boston University research suggests new pathways for cancer progression
6. Possible new pathway can overcome glioblastoma resistance
7. Plant flavonoid luteolin blocks cell signaling pathways in colon cancer cells
8. TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers
9. MS May Take a Different Pathway Than Previously Thought
10. Traumatic injury sets off a genomic storm in immune system pathways
11. New gene study of ADHD points to defects in brain signaling pathways
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology: